Linzess sales boost Forest, Ironwood
This article was originally published in Scrip
Executive Summary
Forest Laboratories started its 2014 fiscal year off on a high note with product sales and earnings that beat consensus estimates, including sales of Linzess (linaclotide) that were almost double the total anticipated by equity analysts.